Palvella Therapeutics, Inc. Common Stock (PVLA)

• Market cap: $132M
• 1 day: -1.67%
• 5 days: -9.23%
• 1 month: -9.23%
• 3 months: -9.23%
• 6 months: -9.23%
• Year to date: -9.23%
• 1 year: -9.23%
• 5 years: -9.23%
• 10 years: -9.23%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.